Biotech Stocks Declining (AVEO Pharmaceuticals, Seattle Genetics, Medivation, Inc, Ariad Pharmaceuticals)

Lakeway, TX -- (SBWIRE) -- 02/14/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) fell 0.14% and is trading at $7.34. AVEO Pharmaceuticals, Inc. is a cancer therapeutics company discovering, developing and commercializing targeted cancer therapies. The Company’s Human Response Platform, a method of building preclinical models of human cancer, provides the Company with insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics.

How Should Investors Trade AVEO After The Latest Earnings Report? Find Out Here

Seattle Genetics, Inc. (NASDAQ:SGEN) is lower 0.86% and is trading at $27.52. Seattle Genetics, Inc. (Seattle Genetics), is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.

Is SGEN a Buy After The Solid Earnings? Get Free Trend Analysis Here

Medivation, Inc. (NASDAQ:MDVN) fell 0.89% and is trading at $53.75. Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc. (Astellas), the Company is developing MDV3100 for multiple stages of advanced prostate cancer.

How Should Investors Trade MDVN After The Recent Movement? Find Out Here

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is lower 1.10% and is trading at $19.86. ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy.

Get Latest News, Updates and Reports For Free On ARIA Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.